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Background: Epidemiologic studies have implicated wartime exposures to acetylcholinesterase (AChE)-inhibiting
chemicals as etiologic factors in Gulf War illness (GWI), the multisymptom condition linked to military service in the
1991 Gulf War. It is unclear, however, why some veterans developed GWI while others with similar exposures did
not. Genetic variants of the enzyme butyrylcholinesterase (BChE) differ in their capacity for metabolizing
AChE-inhibiting chemicals, and may confer differences in biological responses to these compounds. The current
study assessed BChE enzyme activity and BChE genotype in 1991 Gulf War veterans to evaluate possible association
of this enzyme with GWI.
Methods: This case–control study evaluated a population-based sample of 304 Gulf War veterans (144 GWI cases,
meeting Kansas GWI criteria, and 160 controls). BChE enzyme activity levels and genotype were compared, overall,
in GWI cases and controls. Potential differences in risk associated with cholinergic-related exposures in theater were
explored using stratified analyses to compare associations between GWI and exposures in BChE genetic and
enzyme activity subgroups.
Results: Overall, GWI cases and controls did not differ by mean BChE enzyme activity level or by BChE genotype.
However, for the subgroup of Gulf War veterans with less common, generally less active, BChE genotypes (K/K,
U/AK, U/A, A/F, AK/F), the association of wartime use of pyridostigmine bromide (PB) with GWI (OR = 40.00,
p = 0.0005) was significantly greater than for veterans with the more common U/U and U/K genotypes (OR = 2.68,
p = 0.0001).
Conclusions: Study results provide preliminary evidence that military personnel with certain BChE genotypes who
used PB during the 1991 Gulf War may have been at particularly high risk for developing GWI. Genetic differences
in response to wartime exposures are potentially important factors in GWI etiology and should be further evaluated
in conjunction with exposure effects.
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Studies of veteran populations in the U.S. and other
countries have consistently described a profile of chronic
symptoms that afflict veterans of the 1991 Gulf War at
significantly excess rates, compared to other veteran
groups. This condition, commonly known as Gulf War
illness (GWI), is estimated to affect between one fourth
and one third of the nearly 700,000 U.S. veterans who
served in the 1991 conflict [1-4]. Gulf War illness is
characterized by multiple concurrent symptoms that in-
clude persistent headaches, cognitive difficulties, wide-
spread pain, fatigue, gastrointestinal problems, and other
chronic abnormalities—symptoms not accounted for by
medical or psychiatric conditions routinely diagnosed in
clinical practice. Longitudinal studies indicate that few
veterans have recovered or substantially improved over
time [2,5,6].
Despite extensive research related to the health of Gulf
War veterans, a detailed understanding of the specific
nature and causes of GWI has not yet been conclusively
established. Diverse biological alterations have been
described in veterans with Gulf War illness compared to
healthy controls, including significant differences in
brain structure and function [7-10] as well as autonomic
[11-13], immune [14-17], and endocrine [18,19] parame-
ters. Epidemiologic studies of Gulf War veterans consist-
ently indicate that GWI is not associated with combat
stressors, when effects of other wartime exposures are
taken into account, and that rates of psychiatric illness
associated with the brief 1991 conflict are substantially
lower than for other wars [2,20,21].
A variety of potentially hazardous chemicals encoun-
tered by some Gulf War military personnel have been
suggested as causes or contributors to GWI. These include
multiple exposures with the potential to cause adverse
neurological effects, including low-level exposure to chem-
ical nerve agents, use of pyridostigmine bromide (PB) pills
given prophylactically as a protective measure against
nerve agents, and extensive use of pesticides. [2,21-23].
Few measurements were made during the war that
documented the levels and concentrations of exposures
experienced by individual veterans. However, useful in-
formation on deployment-related exposures has been
provided by government investigations utilizing a variety
of methods, including extensive command and field in-
terviews, record reviews, event and exposure simula-
tions, and modeling efforts [2]. Estimates provided by
the Department of Defense (DOD) indicate that about
100,000 U.S. military personnel were potentially ex-
posed, in March 1991, to low levels of the nerve agents
sarin and cyclosarin in connection with demolitions at a
large Iraqi munitions compound near Khamisiyah, Iraq
[24]. Government reports also indicate that about half of
American ground troops took PB tablets in varyingamounts, and that military personnel used a wide range
of pesticides and insect repellants in different combina-
tions, often at excessive levels [22,23].
Sarin and cyclosarin are organophosphate compounds,
PB is a carbamate compound, and the many pesticides
used by military personnel in the Gulf War included a
variety of both organophosphates and carbamates. These
chemicals are acetylcholinesterase (AChE) inhibitors;
that is, their chemical action interferes with breakdown
of the neurotransmitter acetylcholine. These compounds
can be acutely toxic, even fatal, at sufficiently high doses.
But their long-term effects, particularly in relation to re-
peated, lower-dose exposures, are less well understood.
Epidemiologic studies of Gulf War veterans consistently
indicate that veterans who report using PB and pesticides
have significantly higher rates of GWI than veterans who
did not use these compounds in theater [21,25-27].
An important question concerning GWI relates to
why some personnel developed chronic symptoms after
the war while others with similar wartime experiences
and exposures remained healthy. One possibility is that
vulnerability to certain deployment-related exposures
differed as a result of individual variability in the bio-
logical processes that neutralize these exposures and
confer protection from acute and/or chronic adverse ef-
fects. Recent reports from both the federal Research Ad-
visory Committee on Gulf War Veterans’ Illnesses [20]
and the Institute of Medicine [4] have suggested that
genetic factors may have played a role in the develop-
ment of GWI and have urged additional research to
evaluate this possibility.
Acetylcholinesterase-inhibiting chemical exposures inter-
act with a variety of circulating enzymes in humans, in-
cluding two cholinesterases—butyrylcholinesterase (BChE)
and AChE. Butyrylcholinesterase is present at more than
10 times the level of AChE in whole blood, but its physio-
logical functions are not completely understood. It is
known to provide protection from adverse effects of car-
bamates, organophosphates, and other chemicals by acting
as a scavenger, binding them molecule-for-molecule,
thereby sparing circulating levels of AChE [28].
There is one gene for BChE, located on chromosome
3q26, with multiple nucleotide variations identified at
this locus [28]. The wild type “U” allele is most common,
followed by the K, A, and F mutations. The less common
variants are associated, on average, with lower enzyme
activity levels and/or binding affinity for AChE-inhibiting
compounds, rendering individuals especially sensitive to
a number of chemicals [28-30]. Individuals who are AA
homozygotes, for example, experience prolonged apnea
and paralysis—up to two hours—if given the muscle re-
laxant succinylcholine for surgery at doses that normally
act only for several minutes [30]. Limited evidence also
suggests that some BChE genetic variants may be more
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ing PB [28,31].
We report here on results from a case–control study
that assessed BChE genotype and enzyme activity in vet-
erans of the 1991 Gulf War. Data for the study were col-
lected in 2001 in connection with a multipart project
that evaluated deployment experiences, genetic variabil-
ity, and autonomic nervous system function in veterans
of the 1991 Gulf War.
Methods
Study design and participants
The study utilized a case–control design to evaluate
BChE activity and genotype in relation to GWI and de-
ployment characteristics in a population-based sample of
304 Gulf War veterans. Detailed information on the
study sample and data collection have previously been
described [21]. Study participants included 144 GWI
cases and 160 controls, with cases defined according to
Kansas GWI criteria [1]. Briefly, the Kansas GWI case
definition requires that veterans endorse moderately se-
vere or multiple chronic symptoms in at least three of
six defined symptom domains. Veterans are excluded as
GWI cases if they report being diagnosed with any from a
list of chronic medical conditions that might account for
their symptoms, or severe psychiatric conditions that
might preclude their ability to accurately report symp-
toms. Veteran controls had insufficient symptoms to meet
GWI case criteria, and reported no exclusionary medical
or psychiatric diagnoses. The study questionnaire also in-
cluded symptom questions that allowed identification of
veterans who met case criteria for “chronic multisymptom
illness (CMI),” as defined by Fukuda et al. [32] at the U.S.
Centers for Disease Control and Prevention, sometimes
referred to as the “CDC” case definition.
In addition to symptoms and medical conditions, vet-
erans provided information on their demographic and
military characteristics, on 19 experiences and exposures
potentially encountered during their 1990–1991 deploy-
ment, and on the general locations in which they served
in the Gulf War theater of operations.
In conducting this research, investigators complied
with all applicable U.S. regulations regarding the protec-
tion of human subjects. The study protocol was ap-
proved by Institutional Review Boards of the Kansas
Department of Health and Environment and Midwest
Research Institute, and by the Army’s Office of Human
Research Protections. Veteran participants gave both
oral and written informed consent prior to enrolling in
the study.
Laboratory methods
Two 9.5 mL tubes of blood were collected from each
veteran to determine BChE enzyme activity level andgenotype. Phenotype was determined by measuring serum
enzyme activity with benzoylcholine in Na/K phosphate
buffer, as previously described [33]. Inhibition of activity
by dibucaine was used to identify “atypical” (A) and
fluoride-resistant (F) phenotypes. Where unusual dibu-
caine inhibition levels were observed, inhibition by 50 μM
sodium fluoride was measured to distinguish between UA,
UF, AF, FF, and FS phenotypes [34,35].
DNA was isolated and amplified by polymerase chain
reaction, followed by restriction enzyme digestion, to de-
termine genotype at the BChE polymorphic site Ala/Thr
539 (K variant). Amplification created a Mae III restric-
tion site when the K-variant ACA codon (Thr 539) was
present [35]. DNA from samples that phenotyped as het-
erozygous for the BChE F variant were amplified and se-
quenced to determine which of three reported DNA
mutations were responsible for the fluoride resistance
[36,37]. Similarly, DNA from samples that phenotyped
as heterozygous for the atypical variant (Asp70Gly) were
amplified and sequenced to confirm the presence of the
codon for Gly70 [38]. Laboratory analyses were per-
formed by technicians who had no information on char-
acteristics of veterans’ health or military service.
Data analyses
Mean BChE enzyme activity levels were determined for
each genetic type identified in the sample, for GWI cases
and controls, and for demographic subgroups. Mean
values were compared using Student’s t-tests. Propor-
tional comparisons between veteran subgroups were
assessed using chi-square statistics except as noted.
Associations between GWI and each “cholinergic” ex-
posure queried for the study (that is, exposures with the
potential for cholinergic effects) were evaluated in vet-
eran subgroups defined by BChE activity and genotype.
Comparably-sized BChE activity subgroups were defined
according to whether veterans’ BChE activity level, mea-
sured at the time of the study, was equal to/above vs.
below the median level for the sample as a whole (1.09
μmoles benzoylcholine per minute per mL serum).
Prevalence odds ratios (ORs) for GWI/exposure associa-
tions were calculated separately for BChE activity sub-
groups and compared across strata.
Similar analyses compared associations between GWI
and exposures in BChE genetic subgroups. Because of
the relatively small number of individuals with each of
the less common, and generally less active, BChE geno-
types (K/K, U/AK, U/A, A/F, AK/F) in the sample, vet-
erans with these genotypes were combined into a single
BChE “less common variants” (BChE-LCV) subgroup, for
comparison to veterans with U/U and U/K genotypes.
Prevalence odds ratios (ORs) for GWI/exposure associa-
tions were calculated separately for BChE genetic sub-
groups and compared across strata.
Table 1 Butyrylcholinesterase (BChE) enzyme activity in
Gulf War veterans
n BChE mean
(SD) activity*
All veterans in study 304 1.10 (0.26)
BChE genotype
U/U 189 1.19 (0.24)
U/K 87 1.01 (0.21)
K/K 13 0.80 (0.15)
U/AK 10 0.76 (0.18)
U/A 3 1.03 (0.12)
A/F 1 0.92
AK/F 1 0.69
Common variants combined (U/U and U/K) 276 1.13 (0.24)
Less common variants combined
(K/K, U/AK, U/A, A/F, AK/F)
28 0.81 (0.17)↑
Race
White 265 1.10 (0.26)
Black 26 1.07 (0.24)
Other 8 1.12 (0.23)
Sex
Male 282 1.11 (0.25)
Female 22 0.95 (0.26)↑↑
Age at time of study
29-39 189 1.10 (0.25)
40-49 77 1.14 (0.27)
50+ 38 1.05 (0.23)
Gulf War illness case status
Gulf War illness cases 144 1.10 (0.24)
Gulf War veteran controls 160 1.10 (0.27)
BChE = butyrylcholinesterase, SD = standard deviation.
*Mean enzyme activity expressed in μmoles benzoylcholine hydrolyzed per
minute per mL of serum.
↑Mean enzyme activity differs significantly from U/U and U/K (p < 0.001).
↑↑Mean enzyme activity differs significantly from males (p = 0.003).
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lie the gene-exposure interaction identified by the study,
post-hoc analyses were conducted to determine whether
characteristics and exposures reported by the BChE-LCV
genetic subgroup differed from those of other veterans in
the study. Additional post-hoc analyses assessed whether
the identified interaction might have been an anomaly of
the Kansas GWI case criteria used for the study. For this
assessment, symptom data were used to “reassign” case/
control status for all 304 veteran subjects, with case status
determined using the CMI criteria of Fukuda et al. [32].
Prevalence odds ratios (ORs) were again calculated separ-
ately for BChE genetic subgroups to assess the association
of illness with exposure in CMI cases and controls. All
statistical analyses were conducted using SAS statistical
software, version 9.2 [39].
Results
Study population
Health, demographic, and military characteristics of the
study population are described in detail elsewhere [21].
Gulf War illness cases were similar to controls with re-
spect to sex (cases: 8% female; controls: 7% female; p =
0.80) and age (mean age cases: 37.4; mean age controls:
36.9; p = 0.53) at study intake, but differed significantly
by race (cases: 83% white; controls 94% white; p = 0.01).
BChE activity and genotype in Gulf War veterans
Mean BChE enzyme activity levels are shown in Table 1
for all veterans combined, for each BChE genotype in
the sample, for demographic subgroups, and for GWI
cases and controls. As expected, the BChE-LCV sub-
group of veterans exhibited, on average, significantly
lower BChE activity levels than veterans with U/U and
U/K genotypes. Enzyme activity did not vary significantly
by race or by age. Similar to the general population [40],
female Gulf War veterans had significantly lower BChE
activity than males. The mean BChE activity level of
GWI cases was nearly identical to that of controls.
When the sample was evaluated overall, the BChE
genetic profiles of GWI cases and controls were also
nearly identical (Table 2). That is, no significant associ-
ation between GWI case status and BChE genotype was
found, either in the distribution of specific BChE vari-
ants or in the overall proportion of cases and controls
with less common BChE genotypes.
Association between GWI and exposures in relation to
BChE activity and genotype
We assessed whether BChE variability played a role in
observed associations between GWI and deployment ex-
posures that potentially had cholinergic effects. This in-
cluded all variables related to pesticide exposures and
PB use, and one variable possibly related to low-levelnerve agent exposure (hearing chemical alarms). No sig-
nificant differences were identified between Gulf War
veteran subgroups defined by BChE enzyme activity.
That is, associations between GWI and exposures were
similar in veterans with lower versus higher BChE en-
zyme activity measured at the time of the study (results
not shown in tables).
In evaluating associations between GWI and choliner-
gic exposures in relation to BChE genotype, there were
no significant differences between U/U and U/K geno-
type subgroups (Table 3). For the BChE-LCV subgroup,
however, GWI risk was dramatically elevated for vet-
erans who reported taking PB pills during deployment
(OR = 40.00, p = 0.0005, Fisher’s exact test). Use of PB
pills was also associated with GWI among veterans with
Table 2 Distribution of butyrylcholinesterase genotype in
Gulf War illness cases and controls
Total sample
(n = 304)
GWI cases
(n = 144)
Controls
(n = 160)
BChE genotype n (%) n (%) n (%)
U/U 189 (62%) 89 (62%) 100 (62%)
U/K 87 (29%) 41 (28%) 46 (29%)
K/K 13 (4%) 7 (5%) 6 (4%)
U/AK 10 (3%) 5 (3%) 5 (3%)
U/A 3 (1%) 1 (<1%) 2 (1%)
A/F 1 (<1%) 0 (0%) 1 (<1%)
AK/F 1 (<1%) 1 (<1%) 0 (0%)
Less common
variants combined
(K/K, U/AK, U/A. A/F, AK/F)
28 (9%) 14 (10%) 14 (9%)
BChE = butyrylcholinesterase, GWI = Gulf War illness.
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(OR = 2.68 for U/U and U/K subgroups combined, p =
0.0001). The difference between ORs for veterans in the
BChE-LCV subgroup and veterans with U/U and U/K
genotypes was statistically significant (p = 0.019, Breslow-
Day test for homogeneity of ORs), indicating a significant
interaction between exposure and BChE genotype. This
interaction indicates a substantially increased risk for
GWI for the subgroup of Gulf War veterans with less
common BChE genotypes (K/K, U/AK, U/A, A/F, and
AK/F) who used PB during deployment.
No other significant interactions were identified in rela-
tion to BChE genotype. That is, the association of GWI
with veteran-reported use of pesticides and experiencesTable 3 Association of Gulf War illness with exposures with p
genetic subgroup
Butyrylch
U/U homozygotes
(n = 89 GWI cases, 100 controls) (n = 4
Experience/exposure % cases
exposed
% controls
exposed
OR* (95% C.I.) % cases
exposed
Took PB (pyridostigmine
bromide) pills
67% 48% 2.25 (1.23–4.11) 74%
Wore uniforms treated
with pesticides
22% 8% 3.07 (1.27–7.44) 37%
Used pesticide cream
or spray on skin
55% 31% 2.75 (1.50–5.02) 62%
Living area sprayed
with pesticides
21% 18% 1.23 (0.59–2.57) 24%
Heard chemical
alarms sounded
57% 57% 1.02 (0.57–1.82) 62%
BChE = butyrylcholinesterase, GWI = Gulf War illness, OR = prevalence odds ratio, C.I
*OR compares GWI cases with controls within each genetic subgroup.
↑OR for veterans with less common BChE variant genotypes differs significantly frompossibly linked to chemical weapons exposures did not
differ among veterans in the U/U, U/K, and BChE-LCV
genetic subgroups.
The striking interaction between BChE genotype and
the use of PB pills during deployment prompted add-
itional evaluations to assess whether the observed effect
might have been the result of other factors, such as an
inconsistency in the pattern of exposures reported by
BChE variants, or an anomaly of the GWI case defin-
ition used for the study. Overall, veterans in the BChE-
LCV subgroup were nearly identical to veterans in the
other two subgroups with respect to sex, age, education,
rank, branch of service, deployment locations, and pro-
portion reporting deployment exposures. For example,
58% of veterans in the BChE-LCV subgroup reported
using PB pills, compared to 57% of those with U/U and
U/K genotypes (p = 0.93). Similarly, 19% of the BChE-
LCV subgroup reported wearing uniforms treated with
pesticides, compared to 18% of veterans with U/U and
U/K genotypes (p = 0.90).
Additional analyses indicated that the elevated GWI
risk associated with the use of PB by the BChE-LCV
subgroup of veterans was not uniquely tied to the
Kansas GWI case definition (Table 4). A similar pattern
was observed when case status was reassigned, based on
the chronic multisymptom illness criteria of Fukuda
et al. [32], yielding 187 cases and 117 controls. Using ei-
ther case definition, chronic symptomatic illness was sig-
nificantly associated with use of PB pills for the sample
as a whole. However, the PB-illness association was sub-
stantially more pronounced in the subgroup of veterans
with less common, and generally slower acting BChE ge-
notypes (K/K, U/AK, U/A, A/F, and AK/F).otential cholinergic effects, by butyrylcholinesterase
olinesterase genetic subgroup
U/K heterozygotes
1 GWI cases, 46 controls)
Less common BChE variants
(K/K, U/AK, U/A, A/F, AK/F)
(n = 14 GWI cases, 14 controls)
% controls
exposed
OR* (95% C.I.) % cases
exposed
% controls
exposed
OR* (95% C.I.)
41% 3.98 (1.57–10.1) 92% 23% 40.0↑ (3.58–447)
11% 4.92 (1.59–15.2) 29% 8% 4.80 (0.46–50.2)
28% 4.23 (1.71–10.5) 50% 43% 1.33 (0.31–5.91)
17% 1.47 (0.51–4.29) 21% 14% 1.64 (0.23–11.7)
44% 2.00 (0.84–4.79) 64% 50% 1.80 (0.40–8.18)
. = confidence interval.
OR for veterans with U/U and U/K genotypes, p = 0.019.
Table 4 Association of pyridostigmine bromide use with chronic illness in BChE subgroups: evaluation using two case
definitions
Use of PB by all Gulf War veterans
(n = 304)
Use of PB by butyrylcholinesterase genetic subgroups
Common BChE variants
(U/U and U/K) (n = 276)
Less common BChE variants
(K/K, U/AK, U/A, A/F, AK/F) (n = 28)
Case definition % cases
exposed
% controls
exposed
OR (95% C.I.) % cases
exposed
% controls
exposed
OR (95% C.I.) % cases
exposed
% controls
exposed
OR (95% C.I.)
GWI
(Kansas case definition)*
72% 44% 3.21 (1.97–5.24) 69% 46% 2.68 (1.62–4.44) 92% 23% 40.00 (3.58–447)
CMI
(CDC case definition)↑
63% 46% 1.99 (1.23–3.22) 62% 49% 1.73 (1.05–2.84) 78% 22% 11.37 (1.65–78.4)
BChE = butyrylcholinesterase, PB = pyridostigmine bromide, CDC = U.S. Centers for Disease Control and Prevention, OR = prevalence odds ratio, C.I. = confidence
interval.
*Gulf War illness, as defined in Steele [1].
↑Chronic multisymptom illness, as defined in Fukuda et al. [32].
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More than 23 years after the cease fire that ended Oper-
ation Desert Storm in 1991, our understanding of the
specific factors that led to GWI remains incomplete.
The present study provides the first direct evidence sug-
gesting that interaction between genetic factors and a
chemical exposure associated with Gulf War service may
have contributed to the development of GWI. Specific-
ally, the subgroup of Gulf War veterans in our study
with less common, and generally less active, genetic vari-
ants of the enzyme BChE were at substantially increased
risk for GWI if they took PB pills during deployment.
This genetic subgroup constituted 9% of the veterans in
our sample, and included all homozygous carriers of the
BChE K allele and heterozygous carriers of BChE A and
F alleles. The identified interaction of BChE genotype
with veterans’ use of PB was a singular observation and
requires corroboration in other veteran groups. How-
ever, this initial finding comes from a representative
sample of Gulf War veterans, was highly significant, and
was not explainable by study factors such as differential
reporting of PB use or how GWI cases were defined.
This study therefore provides a foundation and model
for an expanded investigation of gene-exposure interac-
tions that potentially explain why some military personnel
developed chronic illness in connection with Gulf War
service while others, with similar deployment experiences
and exposures, remained healthy. The association of GWI
with BChE genotype was specific to veterans who reported
using PB in our sample, and did not occur in connection
with other wartime experiences like hearing chemical
alarms and using different types of pesticides. Multiple
genes can potentially contribute to differences in individ-
ual responses to cholinesterase inhibitors and other chem-
ical exposures [41,42]. It is therefore possible that other
genetic factors, such as polymorphisms of the paraoxonase
(PON1) enzyme, might have played a role in the develop-
ment of chronic illness in connection with Gulf War
exposures.Genetic variability in biological processes that neutralize
AChE inhibitors has long been hypothesized to underlie
differences in vulnerability to these compounds—in Gulf
War veterans and in other exposed populations [2,28,43,44].
Although this is the first study to demonstrate a specific
gene-exposure interaction in the risk for GWI, our find-
ings are consistent with preliminary indications that un-
anticipated effects of Gulf War exposures may be linked
to BChE genetic variability.
A 1995 case report described the experience of an
Israeli soldier who developed severe symptoms when
taking PB during the Gulf War at the recommended
dosage (30 mg., three times per day) [31]. This soldier
was found to be homozygous for the BChE A allele, and
had a history of post-anesthesia apnea. Further investiga-
tion revealed that his serum BChE had only one-third
normal activity, and very poor binding capacity for car-
bamates, including PB. Later, results from a DOD-
sponsored study described in a federal project report
suggested that BChE genotype may be associated with
chronic symptoms in Nebraska Gulf War veterans [45].
Investigators determined BChE allele frequencies in 226
Gulf War veterans. Of 11 carriers of the A or F alleles,
eight (73%) had previously identified themselves as GWI
“cases,” suggesting a potential link between GWI and
BChE variants.
Our general finding that mean BChE enzyme activity,
measured at the time of the study, did not differ between
GWI cases and controls parallels results from two previ-
ous studies [46,47]. However, a 2000 study indicated that
BChE activity was significantly higher in 152 British Gulf
War veterans with health concerns, compared to age and
sex-matched individuals in the general population [48].
Variability in PON1 has also been suggested as a pos-
sible contributing factor to GWI. Four studies have re-
ported on one or more PON1-related variables in
relation to Gulf War service, yielding a somewhat mixed
picture. The first, studying a Navy Seabees unit, reported
that the 12 veterans with the most severe symptomatic
Steele et al. Environmental Health 2015, 14:4 Page 7 of 10
http://www.ehjournal.net/content/14/1/4illness were significantly more likely to have low PON1
type Q arylesterase activity [46]. Two larger studies of
British Gulf War veterans indicated that PON1 para-
oxon activity was significantly lower in ill Gulf War vet-
erans, overall, than comparison groups [48,49]. A more
recent study of Iowa Gulf War veterans reported no
associations with PON1 activity [47]. None of these
studies, however, looked specifically at the question of
whether associations between GWI and exposures dif-
fered with BChE or PON1genotype or phenotype.
BChE in other exposed populations and in animal models
The physiological functions of BChE are not well under-
stood. Enzyme activity varies with BChE genotype, as
demonstrated here, but is also temporarily reduced by
certain drugs and environmental exposures. Although
BChE genotype has previously been hypothesized to
contribute to differences in susceptibility to adverse ef-
fects of cholinergic drugs and pesticides [28], few studies
have evaluated BChE-associated risk in exposed popula-
tions. A 1996 study reported that “non-usual” BChE var-
iants were significantly overrepresented among Brazilian
farmers exposed to carbamate and organophosphate pesti-
cides who exhibited mild signs of poisoning [50]. Related
findings, from a more recent assessment of pesticide-
exposed farm workers, indicate that of 256 candidate
single nucleotide polymorphisms (SNPs) in 30 genes po-
tentially related to pesticide metabolism, the strongest cor-
relates of reduced cholinesterase activity, over four time
points, were two SNPs in the BChE gene [51].
Studies in several animal models also suggest a role
for BChE in providing a protective biological response
to PB [52,53]. This includes findings that delayed central
nervous system effects resulting from low-dose PB ex-
posure occurred only in a genetic strain of rats with re-
duced BChE activity levels, not in a standard strain with
normal BChE activity [54,55]. Additional insights regard-
ing BChE activity in the brain come from studies sug-
gesting that BChE has physiological actions in addition
to its scavenging function. These include indications that
BChE becomes biologically active in the brain under
conditions in which acetylcholine is elevated, acting dir-
ectly to reduce acetylcholine levels [56-58].
Current BChE findings in context
Several aspects of our findings deserve emphasis. First,
the association between BChE genotype and GWI was
not identified when all Gulf War veterans were evalu-
ated together, but was only apparent in relation to PB
use. This underscores the importance of assessing risk
factors for GWI, including genetic risk factors, in appro-
priate subgroups. It also illustrates an important principle
that is too often overlooked: genetic polymorphisms that
produce reduced capacity to neutralize specific chemicalswould generally not be expected to produce health conse-
quences for individuals who are not exposed to those che-
micals. It is therefore essential that studies whose purpose
is to assess genetic factors in relation to GWI carefully
evaluate those associations in connection with relevant
exposures.
It is important to note that GWI was also associated
with PB use in veterans with the common U/U and U/K
genotypes in our sample, although the association was
not as strong as in the BChE-LCV subgroup. This indi-
cates that PB was a risk factor for GWI for reasons other
than the apparent genetic vulnerability identified in this
study. As detailed in a 2008 federal committee report, Gulf
War Illness and the Health of Gulf War Veterans, PB is
the most consistently-identified risk factor for GWI across
all epidemiologic studies that adjusted for effects of con-
current wartime exposures [2]. This broader role for PB as
a risk factor for GWI is supported by identification of
dose–response effects in several studies [25,26,59], and by
studies linking PB use during the Gulf War to brain and
hypothalamic-pituitary-adrenal alterations in Gulf War
veterans evaluated many years later [9,18,19].
The association of PB with GWI differed by BChE
genotype, but was not associated with BChE enzyme ac-
tivity measured at the time of the study. While genetic
type is the most sustained correlate of BChE activity
over time, it is just one factor that potentially contrib-
uted to reduced BChE activity levels in theater. Inde-
pendent of genotype, it is likely that BChE activity levels
were reduced, to varying degrees, among some Gulf War
personnel in theater, particularly during periods of sus-
tained exposure to pesticides, PB, and other cholinester-
ase inhibitors. Such “situational” reductions in BChE
activity might have rendered veterans vulnerable to de-
veloping chronic symptoms via mechanisms similar to
those that contributed to GWI in the BChE-LCV sub-
group of veterans.
Our finding of a significant interaction between PB
and BChE genotype in the risk for GWI can only be
considered preliminary, since it has not been evaluated
in other veteran groups. If corroborated, this interaction
would apply to only a subgroup of veterans who devel-
oped GWI. It is not possible to accurately predict the
number of GWI cases associated with this interaction. A
very speculative estimate, based on our results, would
rely on our observation that among all veterans in our
sample who carried “at risk” BChE genotypes and also
used PB during the war, 80% became GWI cases, consti-
tuting 9% of all cases in our study. If, overall, 9% of the
175,000-233,000 U.S. Gulf War veterans with GWI
[2,4,20] became ill as a result of an interaction between
PB use and BChE genotype, an upper limit of 16,000-
21,000 affected veterans might be inferred. This estimate
is tempered by uncertainties surrounding the diversity of
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itional genetic factors that potentially contributed to vet-
erans’ risk of developing GWI.
Our study had several limitations. Most importantly,
our sample was only large enough to include 28 veterans
with the less common BChE genotypes, disallowing a
detailed assessment of the risk associated with individual
genotypes, or in-depth multivariable assessment of all
exposures in this subgroup. In this relatively small
subgroup, the confidence interval for the observed asso-
ciation was wide, although the point estimate was ex-
tremely high (OR = 40.0) and statistically significant. It is
doubtful that an association of this magnitude would be
an artifact of confounding by another exposure, espe-
cially since other potentially cholinergic exposures did
not significantly interact with BChE genotype in our
sample.
Additional limitations, common to other Gulf War
studies, include our use of self-reported symptoms and
deployment exposures, the only methods currently avail-
able to assess GWI and most aspects of Gulf War de-
ployment. Usual concerns related to recall bias as an
explanation for exposure-illness associations in Gulf
War studies are less a concern for our findings, however,
which relied on objective laboratory measures of both
BChE genotype and activity. Veterans were unaware of
their BChE genotype in reporting both symptoms and
exposures, and did not report PB use differentially by
genotype.
An important strength of our study is the sample,
drawn randomly from a defined population. This pro-
vides confidence that our findings are more likely to be
comparable to the larger Gulf War veteran population
than findings from registry or clinical samples. Our re-
sults also indicate that use of the Kansas GWI case def-
inition to determine case status was a strength. The
Kansas GWI criteria appear to define a profile of symp-
tomatic illness that is more specific to service in the
1991 Gulf War than other case definitions in use [1,21].
Overall, our finding of a significant interaction be-
tween PB use and BChE genotype in the risk for GWI is
provocative, and possibly of great importance. If corrob-
orated, it indicates that susceptible military personnel
should not take PB, just as some individuals are cur-
rently not given succinylcholine when a genetic defi-
ciency of BChE is suspected. This potentially has far
reaching implications for U.S. military policy, which cur-
rently directs prophylactic use of PB as a protective
measure for troops who are at risk for exposure to the
nerve agent soman [60].
Conclusions
The specific causes and biological nature of Gulf War ill-
ness have yet to be adequately characterized. Our resultsillustrate complexities inherent in identifying either gen-
etic factors or wartime exposures as risk factors for GWI
and the need to assess both. Findings from this and re-
lated studies indicate that the long-sought “smoking
gun” pointing to the cause of GWI may differ for differ-
ent subgroups of veterans. Certainly, the magnitude of
the association of GWI with the gene-exposure inter-
action identified here, if replicated in other groups, indi-
cates that PB is a strong “smoking gun” candidate for
the subgroup of Gulf War veterans with identified BChE
genotypes.
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